KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Research & Development (2016 - 2026)

Palvella Therapeutics has reported Research & Development over the past 9 years, most recently at $13.6 million for Q3 2022.

  • Quarterly Research & Development fell 28.24% to $13.6 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $55.0 million through Sep 2022, down 11.24% year-over-year, with the annual reading at $22.8 million for FY2025, 180.22% up from the prior year.
  • Research & Development was $13.6 million for Q3 2022 at Palvella Therapeutics, up from $11.9 million in the prior quarter.
  • Over five years, Research & Development peaked at $18.9 million in Q3 2021 and troughed at $7.9 million in Q1 2018.
  • The 5-year median for Research & Development is $13.2 million (2019), against an average of $13.1 million.
  • Year-over-year, Research & Development surged 146.64% in 2018 and then fell 28.24% in 2022.
  • A 5-year view of Research & Development shows it stood at $13.0 million in 2018, then grew by 8.6% to $14.1 million in 2019, then dropped by 24.78% to $10.6 million in 2020, then skyrocketed by 44.63% to $15.4 million in 2021, then fell by 11.51% to $13.6 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Research & Development are $13.6 million (Q3 2022), $11.9 million (Q2 2022), and $14.1 million (Q1 2022).